伴t(8;21)的急性髓系白血病近期疗效分析

Analysis of the recent curative effect on acute myeloid leukemia with t(8;21)

目的研究影响伴t(8;21)急性髓系白血病(AML)近期疗效的因素。方法将可评判疗效的70例伴t(8;21)AML患者根据诱导治疗的疗效分为二组,A组为标准诱导治疗1～2疗程后CR患者和加用中剂量阿糖胞苷(Ara-C)方案治疗后CR患者;B组为经上述治疗后NR患者。对比二组患者性别、年龄、血象、骨髓象、染色体的差异,寻找影响近期疗效的因素。结果B组患者起病时外周血原始细胞比例、骨髓中原始细胞比例明显较A组高(P<0.05),而骨髓中异常中幼粒的比例B组却低于A组(P<0.05)。3例给予了中剂量Ara-C方案诱导治疗的患者,均取得了缓解。结论伴t(8;21)的AML患者起病时外周血及骨髓中原始细胞比例越高,诱导治疗缓解率越低;而骨髓中异常中幼粒比例越高,诱导治疗缓解率也越高。中剂量Ara-C方案可能会提高伴t(8;21)的AML患者诱导缓解率。

Objective To study the factors that affect the recent curative effect on AML with t（8;21）. Methods Divide 70 AML cases with t（8;21） into A and B group, they are all treated with typical induction regiment added middle dosage Ara-C for one or two treatment periods, the group A are CR patients, the group B are NR patients. Compare their sex, age, hemogram, bone marrow and chromsome, we want to find the factors that affect the recent curative effect. Results The patients in B group have higher level of hematopoietic stem cells in peripheral blood and bone marrow （P 〈0.05）, while the level of abnormal myelocytes is lower （P 〈0.05）. The three patients who received middle dosage Ara-C all got remission. Conclusion The higher level of hematopoietic stem cell in AML with t （8;21） patients＇ peripheral blood and bone marrow, the lower the CR rate is; the higher level of abnormal myelocyte in the bone marrow, the higher the CR rate is. And the middle dosage Ara-C regimens possibly can increase the CR rate in AML with t （8;21） patients.